Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/KCT0004115
KCT0004115Completed未知

An Open Label Phase II Study of Tipifarnib in Patients with Previously-Treated, Advanced, HRAS gene Mutant Urothelial Carcinoma

Samsung Medical Center0 sites18 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Enrollment
18
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional Study

Eligibility Criteria

Ages
20?(Year) to o Limit (—)
Sex
All

Inclusion Criteria

  • •For inclusion of a subject in the study, all of the following inclusion criteria must be fulfilled:
  • •1.Subject is at least 20 years of age.
  • •2.Subject has a histologically or cytologically confirmed diagnosis of urothelial carcinoma arising from urinary bladder or upper urinary tract.
  • •3.Subject has been treated with platinum-based chemotherapy for advanced disease. They must have refractory or progressive disease for which there is no further curative therapy available.
  • •Subject has a tumor that carries a missense HRAS mutation according to a standard methodology using Illumina HiSeqTM. (missence non-synonymous HRAS mutation and/or STK11: rs2075606 (T>C))HRAS status may have been assessed either in primary tumor tissue, recurrent or metastatic disease.
  • •4.Subject has consented to provide at least 10 unstained tumor slides for retrospective testing of HRAS gene tumor status.
  • •5.Must have a life expectancy of 3 months or more
  • •6.Subject has measurable disease according to RECIST v1.1 and has relapsed (progressive disease) or is refractory to prior therapy.
  • •7.At least 2 weeks since the last systemic therapy regimen prior to enrolment. Subjects must have recovered to NCI CTCAE v. 4.03 < Grade 2 from all acute toxicities (excluding Grade 2 toxicities that are not considered a safety risk by the Sponsor and Investigator) or toxicity must be deemed irreversible by the Investigator.
  • •8.At least 2 weeks since last radiotherapy if radiation was localized to the only site of measurable disease, unless there is documentation of disease progression of the irradiated site. Patients must have recovered from all acute toxicities from radiotherapy.
  • •9.ECOG performance status of 0 or 1.
  • •10.Acceptable liver function:
  • •a.Bilirubin ? 1.5 times upper limit of normal (x ULN); does not apply to subjects with Gilbert’s syndrome diagnosed as per institutional guidelines.
  • •b.AST (SGOT) and ALT (SGPT) ? 3 x ULN; if liver metastases are present, then ? 5 x ULN is allowed.
  • •11.Acceptable renal function with serum creatinine ? 1.5 x ULN or a calculated creatinine clearance = 60 mL/min using the Cockcroft-Gault or MDRD formulas. Serum potassium with normal or = CTCAE Grade 1 with or without supplementation.
  • •12.Acceptable hematologic status (without growth factor support or transfusion dependency):
  • •a.ANC ? 1500 cells/µL.
  • •b.Platelet count ? 100,000/µL.
  • •c.Hemoglobin ? 9.0 g/dL.
  • •13.Female subjects must be either:
  • •a.Of non-child-bearing potential (surgically sterilized or at least 2 years post-menopausal); or
  • •b.If of child-bearing potential, subject must use an adequate method of contraception consisting of two-barrier method or one barrier method with a spermicide or intrauterine device. Both females and male subjects with female partners of child-bearing potential must agree to use an adequate method of contraception for 2 weeks prior to screening, during, and at least 4 weeks after last dose of trial medication. Female subjects must have a negative serum or urine pregnancy test within 72 hours prior to start of trial medication.
  • •c.Not breast feeding at any time during the study.
  • •14.Written and voluntary informed consent understood, signed and dated.

Exclusion Criteria

  • •For inclusion of a subject in the study, any of the following exclusion criteria must not be fulfilled:
  • •1.Ongoing treatment with an anticancer agent not contemplated in this protocol.
  • •2.Prior treatment (at least 1 full treatment cycle) with an FTase inhibitor.
  • •3.Any history of clinically relevant coronary artery disease or myocardial infarction within the last 3 years, New York Heart Association (NYHA) grade III or greater congestive heart failure, cerebrovascular attack within the prior year, or current serious cardiac arrhythmia requiring medication except atrial fibrillation.
  • •4.Known uncontrolled brain, leptomeningeal or epidural metastases (unless treated and well controlled for at least 4 weeks prior to Cycle 1 Day 1). Subjects that develop brain metastasis during the study may have their treatment interrupted to receive a course of cranial radiation and restart trial medication after a recovery period of at least 1 week. High dose corticosteroids may be employed for the management of cranial radiation but must be tapered off before resuming treatment.
  • •5.Non-tolerable > Grade 2 neuropathy or evidence of unstable neurological symptoms within 4 weeks of Cycle 1 Day 1.
  • •6.Major surgery, other than diagnostic surgery, within 4 weeks prior to Cycle 1 Day 1, without complete recovery.
  • •7.Double primary cancer of other site(s), except for cured ones at the discretion of investigator
  • •8.Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with HIV, or an active infection with hepatitis B or hepatitis C.
  • •9.Subjects who have exhibited allergic reactions to tipifarnib, structural compounds similar to tipifarnib or to its excipients.
  • •10.Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this study.
  • •11.The subject has legal incapacity or limited legal capacity.
  • •12.Dementia or significantly altered mental status that would limit the understanding or rendering of informed consent and compliance with the requirements of this protocol. Unwillingness or inability to comply with the study protocol for any reason.
  • •13.QTcF interval = 470 msecs

Investigators

Similar Trials

Active, not recruiting
Phase 1
A research study to find out whether tipifarnib is safe and effective for the treatment of a lymphoma in the cases of previous treatment have failed.
EUCTR2016-001396-69-ESKura Oncology Inc.,30
Active, not recruiting
Phase 1
A research study to find ou whether tipifarnib is safe and effective for the treatment of a type of cancer that has a specific genetic mutation and for which there is no curative therapy availableAdvanced Non-Hematological Malignancies with HRAS mutationsMedDRA version: 20.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10071971Term: H-ras gene mutationSystem Organ Class: 10018065 - General disorders and administration site conditionsMedDRA version: 20.0Level: PTClassification code 10066474Term: Thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-004535-12-NLKura Oncology, Inc.36
Active, not recruiting
Phase 1
A research study to find ou whether tipifarnib is safe and effective for the treatment of a type of cancer that has a specific genetic mutation and for which there is no curative therapy availableAdvanced Non-Hematological Malignancies with HRAS mutationsMedDRA version: 18.1Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10071971Term: H-ras gene mutationSystem Organ Class: 10018065 - General disorders and administration site conditionsMedDRA version: 18.1Level: PTClassification code 10066474Term: Thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-004535-12-ESKura Oncology, Inc.63
Active, not recruiting
Phase 1
A research study to evaluate the response rate of tipifarnib in patients with locally advanced unresectable or metastasic, relapsed and/or refractory, squamous non-small cell lung cancer with HRAS mutationssquamous non-small cell lung cancer (SQ-NSCLC)MedDRA version: 20.0 Level: LLT Classification code 10025044 Term: Lung cancer System Organ Class: 100000004864
EUCTR2017-004822-13-ESSpanish Lung Cancer Group (SLCG/GECP)18
Active, not recruiting
Phase 1
A research study to find out whether tipifarnib is safe and effective for the treatment of a type of cancer that has a specific genetic mutation and for which there is no curative therapy available.Advanced non-haematological malignancies with HRAS.MedDRA version: 20.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10071971Term: H-ras gene mutationSystem Organ Class: 10018065 - General disorders and administration site conditionsMedDRA version: 20.0Level: PTClassification code 10066474Term: Thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-004535-12-GBKura Oncology, Inc.62